SCHEMBL16213620

SCHEMBL16213620

COc1cc(F)cc(-c2cc(=O)n3ccc(C)cc3n2)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
HSD17B10 Q99714 1/20 0.43
GAA P10253 2/20 0.39
NTRK1 P04629 1/20 0.39
NTRK2 Q16620 1/20 0.39
MAPT P10636 4/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TP53 P04637 2/20 0.38
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
PTGS2 P35354 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8101681 0.84 KDM4E (0.61) KDM4EALDH1A1NPC1RAB9APKM
SCHEMBL8105784 0.83 KDM4E (0.52) KDM4EALDH1A1NPC1RAB9APKM
SCHEMBL7925160 0.81 KDM4E (0.59) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL8100199 0.76 KDM4E (0.64) KDM4EALDH1A1NPC1RAB9APKM
SCHEMBL1658662 0.76 RAD51 (0.49) KDM4EALDH1A1NPC1RAB9APKM
SCHEMBL16375038 0.76 KDM4E (0.49) KDM4EALDH1A1NPC1RAB9APKM
SCHEMBL1661610 0.75 KDM4E (0.62) KDM4EALDH1A1NPC1RAB9APKM
SCHEMBL8101672 0.74 KDM4E (0.65) KDM4EALDH1A1NPC1RAB9APKM
SCHEMBL8108176 0.74 KDM4E (0.56) KDM4EALDH1A1NPC1RAB9APKM
SCHEMBL21902775 0.74 MEN1 (0.55) ALDH1A1GAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014179401-A1 2-ARYLNAPHTHYRIDIN-4-ONES AS POTENT ANTITUMOR AGENTS TARGETING TUMORIGENIC CELL LINES KUO SHENG-CHU 2014-11-06 WO disclosed